WO2017099494A8 - Genome editing composition comprising cpf1, and use thereof - Google Patents
Genome editing composition comprising cpf1, and use thereof Download PDFInfo
- Publication number
- WO2017099494A8 WO2017099494A8 PCT/KR2016/014379 KR2016014379W WO2017099494A8 WO 2017099494 A8 WO2017099494 A8 WO 2017099494A8 KR 2016014379 W KR2016014379 W KR 2016014379W WO 2017099494 A8 WO2017099494 A8 WO 2017099494A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- genome editing
- cpf1
- editing composition
- composition
- technique
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention relates to a genome editing composition comprising Cpf1, a genome editing method using the same, and a technique for preparing transformed eukaryotic organisms.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150174212 | 2015-12-08 | ||
KR10-2015-0174212 | 2015-12-08 | ||
US201662299043P | 2016-02-24 | 2016-02-24 | |
US62/299,043 | 2016-02-24 | ||
KR10-2016-0036381 | 2016-03-25 | ||
KR20160036381 | 2016-03-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2017099494A1 WO2017099494A1 (en) | 2017-06-15 |
WO2017099494A8 true WO2017099494A8 (en) | 2017-08-10 |
Family
ID=59013788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/014379 WO2017099494A1 (en) | 2015-12-08 | 2016-12-07 | Genome editing composition comprising cpf1, and use thereof |
Country Status (2)
Country | Link |
---|---|
KR (2) | KR101897213B1 (en) |
WO (1) | WO2017099494A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11999952B2 (en) | 2021-04-21 | 2024-06-04 | Toolgen Incorporated | Artificially-manipulated neovascularization regulatory system |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3066201T (en) | 2013-11-07 | 2018-06-04 | Massachusetts Inst Technology | Crispr-related methods and compositions with governing grnas |
WO2016073990A2 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
EP3294896A1 (en) | 2015-05-11 | 2018-03-21 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
CN116334142A (en) | 2015-06-09 | 2023-06-27 | 爱迪塔斯医药公司 | CRISPR/CAS related methods and compositions for improving transplantation |
AU2016326711B2 (en) | 2015-09-24 | 2022-11-03 | Editas Medicine, Inc. | Use of exonucleases to improve CRISPR/Cas-mediated genome editing |
EP3433363A1 (en) | 2016-03-25 | 2019-01-30 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
US11236313B2 (en) | 2016-04-13 | 2022-02-01 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
US11123409B2 (en) * | 2016-07-28 | 2021-09-21 | Institute For Basic Science | Method of treating or preventing eye disease using Cas9 protein and guide RNA |
SG11201901306XA (en) * | 2016-08-19 | 2019-03-28 | Toolgen Inc | Artificially engineered angiogenesis regulatory system |
US11499151B2 (en) | 2017-04-28 | 2022-11-15 | Editas Medicine, Inc. | Methods and systems for analyzing guide RNA molecules |
JP2020524497A (en) | 2017-06-09 | 2020-08-20 | エディタス・メディシン,インコーポレイテッド | Engineered CAS9 nuclease |
US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
WO2019103442A2 (en) * | 2017-11-21 | 2019-05-31 | 한국생명공학연구원 | Genome editing composition using crispr/cpf1 system and use thereof |
EP3744844A4 (en) * | 2018-01-23 | 2021-10-20 | Institute for Basic Science | Extended single guide rna and use thereof |
WO2019173942A1 (en) * | 2018-03-12 | 2019-09-19 | Nanjing Bioheng Biotech Co., Ltd | Engineered chimeric guide rna and uses thereof |
KR102177174B1 (en) | 2018-05-18 | 2020-11-10 | 울산대학교 산학협력단 | A retinal degenerated animal model by PDE6B gene deletion and the preparation method thereof |
WO2020028729A1 (en) | 2018-08-01 | 2020-02-06 | Mammoth Biosciences, Inc. | Programmable nuclease compositions and methods of use thereof |
US20210292722A1 (en) * | 2018-08-09 | 2021-09-23 | G+Flas Life Sciences | Novel crispr-associated protein and use thereof |
CA3109083A1 (en) | 2018-08-09 | 2020-02-13 | G+Flas Life Sciences | Compositions and methods for genome engineering with cas12a proteins |
CN109666684A (en) * | 2018-12-25 | 2019-04-23 | 北京化工大学 | A kind of CRISPR/Cas12a gene editing system and its application |
WO2020142754A2 (en) | 2019-01-04 | 2020-07-09 | Mammoth Biosciences, Inc. | Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection |
KR102493904B1 (en) | 2019-12-13 | 2023-01-31 | 한국생명공학연구원 | Immunodeficient Animal Model Mutated IL2Rg Gene by EeCpf1 and Method for Producing the same |
KR102551876B1 (en) | 2019-12-18 | 2023-07-05 | 한국생명공학연구원 | Composition for Genome Editing or Inhibiting Gene Expression comprising Cpf1 and Chimeric DNA-RNA Guide |
KR102471698B1 (en) * | 2020-03-24 | 2022-11-28 | 연세대학교 산학협력단 | Novel guide RNA and method for diagnosing Coronavirus disease 2019 |
WO2021194172A1 (en) * | 2020-03-24 | 2021-09-30 | 연세대학교 산학협력단 | Novel guide rna and method for diagnosing coronavirus infection 2019 using same |
CN113373170A (en) * | 2021-04-29 | 2021-09-10 | 江西农业大学 | pFNCpfAb/pCrAb double-plasmid system and application thereof |
CN113969281B (en) * | 2021-12-24 | 2022-04-01 | 汕头大学 | Modified CrRNA fragment and African swine fever virus kit |
KR20240020336A (en) | 2022-08-04 | 2024-02-15 | 성균관대학교산학협력단 | Protospacer Adjacent Motif-independent mutant Cas9 protein |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116064532A (en) * | 2012-10-23 | 2023-05-05 | 基因工具股份有限公司 | Composition for cleaving target DNA and use thereof |
AU2014361781B2 (en) | 2013-12-12 | 2021-04-01 | Massachusetts Institute Of Technology | Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing |
US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
-
2016
- 2016-12-07 WO PCT/KR2016/014379 patent/WO2017099494A1/en active Application Filing
- 2016-12-08 KR KR1020160167045A patent/KR101897213B1/en active IP Right Grant
-
2018
- 2018-02-12 KR KR1020180017195A patent/KR101958437B1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11999952B2 (en) | 2021-04-21 | 2024-06-04 | Toolgen Incorporated | Artificially-manipulated neovascularization regulatory system |
Also Published As
Publication number | Publication date |
---|---|
KR20170068400A (en) | 2017-06-19 |
WO2017099494A1 (en) | 2017-06-15 |
KR101897213B1 (en) | 2018-09-11 |
KR20180028996A (en) | 2018-03-19 |
KR101958437B1 (en) | 2019-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017099494A8 (en) | Genome editing composition comprising cpf1, and use thereof | |
WO2017031360A8 (en) | Capture of nucleic acids using a nucleic acid-guided nuclease-based system | |
PL3577110T3 (en) | 8-oxetan-3-yl-3,8-diazabicyclo[3.2.1]octan-3-yl substituted compounds as hiv inhibitors | |
EP3691747A4 (en) | Compositions and methods for editing rna | |
EP3715461A4 (en) | Genome editing composition using crispr/cpf1 system and use thereof | |
WO2015200902A8 (en) | Endophytes, associated compositions, and methods of use thereof | |
EP3271021A4 (en) | Tat-induced crispr/endonuclease-based gene editing | |
EP3427822A4 (en) | Catalyst for preparing 2,5-furancarboxylic acid and method for preparing 2,5-furancarboxylic acid using catalyst | |
EP3456825A4 (en) | Plant genome editing method | |
WO2014144761A3 (en) | Increasing specificity for rna-guided genome editing | |
IL282178A (en) | Products, uses & methods | |
EP3322526A4 (en) | Improved copper-containing multimetallic catalysts, and method for using the same to make biobased 1,2-propanediol | |
EP3594312A4 (en) | Composition, method for producing same, and use thereof | |
WO2016108927A3 (en) | Nitrification inhibitor compositions and methods for preparing the same | |
EP3552017A4 (en) | Compounds, compositions and methods | |
WO2016033437A3 (en) | Polyethers, polyamines, polythioethers, and methods for making same | |
EP3800994A4 (en) | Genome editing in plants | |
GB202017595D0 (en) | Compositions, and methods and uses relating thereto | |
IL284800A (en) | Methods, uses & compositions | |
GB201912024D0 (en) | Methods, products & Uses relating thereto | |
EP3366689A4 (en) | Transition metal complexes, catalyst composition including the same and method for preparing polyolefin therewith | |
GB201813648D0 (en) | Methods, products & uses relating thereto | |
EP3199526A4 (en) | Intermediate for use in synthesizing paroxetine, preparation method for the intermediate, and uses thereof | |
EP3480188A4 (en) | Method for preparing urate-anion exchanger 1 inhibitor | |
GB201912021D0 (en) | Methods, products & Uses relating thereto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16873359 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 02/10/2018) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16873359 Country of ref document: EP Kind code of ref document: A1 |